Abstract: The present invention relates to a new process for preparing the oxazolidinone antibacterial agent Linezolid including key intermediates of oxazolidinones, which comprises the following reactions. Step (a): Reacting 3-fluoro-4-morpholinyl aniline with R-epichlorohydrin Step (b): Carbonylation to form oxazolidinone derivative Step (c): Acetylation of (5R)-5-(chloromethyl)-3-(3-fluoro-4- morpholinophenyloxazolidin- 2-one with sodium acetate to get novel intermediate Step (d): Hydrolysis of (R)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methyl acetate Step (e): Mesylation of (R)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methanol Step (f): Reaction of (R)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methyl methane sulphonate with potassium phthalimide Step (g): Hydrolysis of (S)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methyl phthalimide with hydrazine hydrate Step (h): Acetylation of (S)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methyl amine with acetic anhydride yields Linezolid in high yield.
Novel process for the preparation of Linezolid and its novel intermediates
Field of invention:
The present invention relates to a novel process for the preparation of oxazolidinone antibacterial agent Linezolid and their key intermediates.
Background of the invention:
The oxazolidinone antibacterial agents are a novel synthetic class of antimicrobials with potent activity against a number of human and veterinary pathogens, including gram- positive aerobic bacteria such as multiply- resistant staphylococci and streptococci, anaerobic organisms such as bacteroides and clostridia species & acid-fast organisms such as mycobacterium tuberculosis & mycobacterium avium.
Among lower antibacterial agents, Linezolid is a recent synthetic class of antimicrobial active against a number of pathogenic microorganisms. Linezolid [(S)- N- [[3-[3-fluoro-4- (4-morpholinyl) phenyl]-2-oxo-5-oxazolidinyl] methyl] acetamide] is disclosed in US 5,688,792.
We have developed a novel intermediate and novel process, which is useful to prepare Linezolid. The process has the potential to lower the cost of commercial production of Linezolid. We also discovered novel key intermediates, which are more useful in the currently known process.
It has been found that US pat No: 5, 688, 792 described the process for the preparation of Linezolid as described in scheme.
Scheme-1:
Further is US 2007/0032472 A1 discloses two processes for the preparation of Linezolid in a different route as described in the following scheme.
Scheme-2:
The above mentioned base patent describes the preparation of hydroxy derivative by using hazardous chemical like n-BuLi at the temperature of –78 °C with reported very low yield. This process is not commercially viable and very difficult to handle BuLi as well as the very lower temperature.
In other mentioned patent process other unwanted isomer as well as unspecified impurities forms more, which are very difficult to remove and these impurities are continue to be present in the final drug Linezolid, and during the removal process yield becomes very low.
This has prompted and necessitated further research in an attempt to develop a novel route to avoid the formation of the impurity and to maximize the yield. We have discovered and developed a novel process for the preparation of novel intermediates, which are useful for the preparation of antimicrobial Linezolid. Another objective of the present invention is to provide improved method for the preparation of Linezolid avoiding the drawbacks of the hitherto known process. This process has the potential to significantly lower the cost of commercial production of Linezolid.
Summary of the invention:
A process for the preparation of Linezolid of formula
which comprises;
a) Reaction of 3-fluoro-4-morpholinyl aniline with R-epichlorohydrin to give N- [3- chloro-2-(R)-hydroxypropyl]-3-fluoro-4-morpholinyl aniline.
b) Carbonylation of N- [3-chloro-2-(R)-hydroxypropyl]-3-fluoro-4-morpholinyl aniline to produce (5R)-5-(chloromethyl)-3-(3-fluoro-4-morpholinophenyl)-oxazolidin-2-one.
c) Acetylation of (5R)-5-(chloromethyl)-3-(3-fluoro-4-morpholinophenyl)-oxazolidin-2-one with sodium acetate to produce (R)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methyl acetate.
d) Hydrolysis of (R)-3-(3-fluoro-4- morpholinophenyl)-2-oxo-5-oxazolidinyl methyl acetate with sodium tert. butoxide to provide (R)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methanol.
e) Mesylation of (R)-3-(3-fluoro-4- morpholinophenyl)-2-oxo-5-oxazolidinyl methanol to provide (R)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5- oxazolidinyl methyl methanesulphonate.
f) Reaction of (R)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5- oxazolidinyl methyl methanesulphonate with potassium phthalimide to give (S)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methyl phthalimide.
g) Deprotection of (S)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methyl phthalimide with hydrazine hydrate to provide (S)-3-(3-fluoro-4-morpholinophenyl) -2-oxo-5-oxazolidinyl methyl phthalimide methylamine.
h) Acetylation of (S)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methylamine with acetic anhydride to give Linezolid in high yield and high enantiomeric purity.
The process is described herein where the present invention provides a process to prepare Linezolid
Which comprises;
Step (a): Reacting [3-fluoro-4-morpholinyl aniline] of formula IX with
R-epichlorohydrin
Step (b): Carbonylation of compound structure VIII
Step (C): Acetylation of compound structure VII
Step (d): Hydrolysis of compound structure (VI)
Step (e): Mesylation of compound structure (V)
Step (f): Imidation of compound structure (IV)
Step (g): Hydrolysis of compound structure (III)
Step (h): Acetylation of compound structure (II)
Detailed description of the invention:
The process of the present invention is illustrated in scheme-3:
Scheme-3:
The present invention provides a process for the preparation of novel intermediate of the formula useful for the preparation of Linezolid of formula (I), which comprises;
(i) Reacting the compound 1, 2-difluoro-4-nitrobenzene with morpholine in presence of an organic base and solvent at a temperature in the range of
70-80°C to form the known intermediate of the formula X.
The base such as triethylamine, diisopropylamine, and pyridine, most preferably triethylamine may be used in step (i). Condensation can be carried out by known methods such as those described in US 5, 688, 792.
(ii) Reduction of the compound of the formula X in presence of catalyst and solvent at a temperature in the range of 25-60 °C to form a known intermediate of the formula IX.
The catalyst such as Hydrose, palladium, Raney Nickel, Zinc can be used. Preferably, palladium/Carbon, most preferably Raney Nickel may be used in step (ii). The solvents used may be selected from methanol, water, isopropyl alcohol, ethanol, and ethylacetate. Most preferably, methanol can be used as a solvent. There reaction temperature may preferably between 25-60 °C and most preferably between 40-45 °C. Raney Nickel can be used 10-30 %, preferably 20% catalyst, most preferably 15 %catalyst can be used. The hydrogen gas pressure can apply in the range of 4.0-6.0 kg/cm-2; most preferably 4.0-4.5 kg/cm-2 can be applied.
(iii) Reaction of compound of formula IX with R-epichlorohydrin in presence of alcohol to produce known intermediate of formula VIII.
The solvent such as DMF, DMAc, acetonitrile, sec. butanol, IPA, tert. butanol. Most preferably tert. butanol is used. The quantity of epichlorohydrin is a critical, but for better yield and highest enantiomeric purity. 1.25 molar equivalents are used with respect to 3-fluoro-4-morpholinyl aniline and for reaction completion purpose. The reaction is carried out at boiling temperature for about 16 hrs is required for reaction completion.
(iv) The Carbonylation reaction of compound of formula VIII with dicarbonylimidazolyl by known methods to produce intermediate of formula VII.
The solvent is selected for isolation/crystallization of formula VII from n-butyl acetate, sec. butyl acetate, ethyl acetate, and methyl acetate. Preferably solvent can be ethyl acetate, most preferably solvent can be n-butyl acetate to produce better quality of this intermediate.
(v) The acetylation reaction of compound of formula VII in presence of aprotic solvent to form novel intermediate of formula VI.
The acetylating agents such as sodium acetate (anhydrous), Sodium acetate (mono hydrate), sodium acetate (trihydrate) & potassium acetate can be used. Most preferably, sodium acetate anhydrous can be used in the molar equivalents of 1.0-2.5 equivalents. Most preferably, sodium acetate anhydrous 2.0 molar equivalents can be used.
The solvent selected from aprotic solvents such as dimethyl formamide, dimethyl sulphoxide, and dimethyl acetamide, most preferably dimethyl formamide. The reaction temperature may preferably between 90-130 °C and most preferably 120°C. The reaction time for completion may preferably between 8-12 hrs, most preferably between 8-10 hrs.
(Vi) Hydrolysis reaction of novel intermediate of formula VI in presence of non-polar solvents and in presence of base to produce novel compound of formula V.
Non-polar solvent is selected from tetrahydrofuran, toluene, hexane, most preferable solvent can be tetrahydrofuran. The basic hydrolysis inorganic base is selected from NaOH, Na2CO3, NaHCO3, sodium tert. butoxide, potassium
tert. butoxide. Most preferably sodium tert. butoxide can be used in the 1.0-1.5 molar equivalents. The reaction temperature may preferably between 0-15 °C, most preferably 10-15 °C.
(vii) Mesylation reaction of compound of formula V with methane sulphonyl chloride in presence of methylene dichloride can be carried out by known methods as described in US 5, 688, 792.
(viii) Reaction of compound of formula IV with potassium phthalimide in presence of dimethyl formamide to produce known intermediate of formula III by known methods.
The reaction temperature is between 80-140 °C and most preferably the reaction temperature is 120 °C.
(ix) Reaction of compound of formula III with hydrazine hydrate or aqueous methylamine to produce compound of formula II. These methods of deprotection are known and described in US 5,688, 792.
(x) (S)-N-3- (3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methylamine is reacted with acetic anhydride to produce compound of formula I (Linezolid).
The present invention is more particularly described and explained in the following examples.
Examples:
(S)-N-3- (3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methyl acetamide
Step (1): 3-fluoro-4-morpholinyl nitrobenzene
3, 4-difluoro nitrobenzene (100 gr) is slowly added to a mixture of morpholine (76.6 gr), triethylamine (23 ml) and in presence of acetonitrile solvent (115 ml) at 40-50 °C. Reaction mass is heated for 6 hrs at reflux temperature, cooled to 25-30 °C. Then water (600 ml) is added slowly to the reaction mass and then cooled to 0-5°C. The reaction mixture is stirred for 1 hr. The solid is filtered to give 134 gr of 3-fluoro-4-morpholinyl nitrobenzene.
Step (2): 3-fluoro-4-morpholinyl aniline
Methanol (1. 35 Lt) and 3-fluoro-4-morpholinyl nitrobenzene (134 gr) are added into autoclave and followed by Raney Nickel (20.5 gr). The system was flushed with nitrogen and hydrogen gas. The pressure of hydrogen was set to 4.0 kg/cm-2. The reaction mixture was stirred at 45-50 °C under H2 pressure for 8 hrs & the reaction followed by TLC until completion. The reaction mixture was filtered through celite and the filtrate is distilled off / evaporate solvent completely U/ vaccum at < 50 °C temperature. Reaction mass is cooled to 25-30 °C. To this DM water (400 ml) is added. Stirred for 1 hr at 25-30 °C. The solid is filtered to give 105 gr of 3-fluoro-4-morpholinyl aniline.
Step (3): N- [3-chloro-2-(R)- hydroxy propyl]-3-fluoro-4-morpholinyl aniline
3-fluoro-4-morpholinyl aniline (100 gr) is mixed with R-epichlorohydrin (59 gr) tert- butanol (500 ml) is added and heated for 16 hrs at reflux temperature. The solvent is distilled to give 156 gr of N- [3-chloro-2-(R)- hydroxy propyl]-3-fluoro-4-morpholinyl aniline.
Step (4): (5R)-5-(chloromethyl)-3-(3-fluoro-4-morpholinophenyl)-oxazolidin-2-one
N- [3-chloro-2-(R)- hydroxypropyl]-3-fluoro-4-morpholinyl aniline (156 gr) is dissolved in methylene dichloride (1.5 Lt), diimidazolyl carbonyl (87.4 gr) is added at room temperature, stirred for 24 hrs at 25-30 °C. Then washed thrice with water (750 ml×3). Dry over Na2SO4. Distilled methylene dichloride to give 156 gr of crude (5R)-5-(chloromethyl)-3-[3-fluoro-4- [4-morpholinyl] phenyl]-2-oxazolidinone, which is further isolated and crystallized from n-butyl acetate in combination with Methyltertiarybutylether (1 : 5 ratio) to give 83 gr of (5R)-5-(chloromethyl)-3-(3-fluoro-4-morpholinophenyl)-oxazolidin-2-one.
Step (5): (R)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methyl acetate
(5R)-5-(chloromethyl)-3-(3-fluoro-4-morpholinophenyl)-oxazolidin-2-one (83 gr) is mixed with sodium acetate (43 gr) and dimethyl formamide (320 ml) is added. Reaction mass is heated to 120 °C and stirred for 8-10 hrs. It is then cooled to 25-30 °C. Filter the inorganic salts and washed with DMF (10 ml). DM water (1.0 Lt) is added to round bottom flask. Slowly add above said reaction mass to water at 20-05 °C for a period of 60 min and stirred for 30 min at 20-25 °C. Filtered the precipitated solid, dried the material for 5-6 hrs at 50 °C to give 65 gr of (R)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methyl acetate.
Step (6): (R)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methanol
(R)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methyl acetate (62 gr) is mixed with tetrahydrofuran (300 ml), cooled to 0-5 °C. Slowly added sodium tert-butoxide (17.5 gr) at 0-5 °C and followed by slow addition of DM water (620 ml) at 10-15 °C. The reaction mass is stirred for 30 min at 10-15 °C. After completion of the reaction, methylene dichloride is added (300 ml), further extracted with methylene dichloride (120 ml). Solvent is evaporated completely U/vaccum. The precipitated solid is crystallized from hexane or Isopropylether (150 ml). Isolated solid is filtered and washed with hexane or Isopropylether. Dried the material at 50-55 °C to give 50 gr of (R)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methanol.
Step (7): (R)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methyl methanesulphonate
(R)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methanol (50 gr) and triethylamine (42.6 gr) in methylene dichloride (250 ml) was cooled in ice-bath and treated with methane sulphonyl chloride (38.2 gr). The mixture was stirred for 30 min at 0-5 °C. The precipitated product is filtered and washed with chilled DM water (250 ml). Dried the material at 50-55 °C and recrystallized from Toluene media to give 40 gr of (R)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methyl methanesulphonate.
Step (8): (S)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methyl phthalimide
The mixture of (R)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methyl methanesulphonate (30 gr), potassium phthalimide (19.4 gr) and dimethyl formamide (180 ml) is heated for 2 hrs at 120 °C temperature. The reaction mixture is cooled to 0-5 °C, slowly added 360 ml of DM water and filtered the solid to give 27 gr of (S)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methyl phthalimide.
Step (9): (S)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methyl amine
Methanol (150 ml) and hydrazine hydrate (16.2 gr) are added to flask containing (S)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methyl phthalimide (25 gr), heated for 1 hr at reflux temperature and cooled to room temperature. Distill off solvent completely U/vaccum at 45 °C. Then water (125 ml) is added to the reaction mass and extracted with methylene dichloride (62 ml×2). The combined extractions were washed with water (62 ml) and the solvent is distilled and product is isolated from Hexane media to give 15 gr of (S)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methylamine.
Step (10): (S)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methyl acetamide
(S)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methylamine (15 gr) is dissolved in ethylacetate (150 ml); acetic anhydride (15 gr) is added dropwise at ambient temperature and stirred for 1 hr. The reaction mixture is then cooled to 0-5 °C. Filtered the solid to give 12 gr of (S)-3-(3-fluoro-4-morpholinophenyl) -2-oxo-5-oxazolidinyl methyl acetamide.
WE CLAIM:
1. A process for the preparation of (R)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl methanol
which comprises;
a) Reacting a compound of formula IX with R-epichlorohydrin to produce a compound of formula VIII, which further converted to chloromethyl oxazolidinone compound of formula VII
b) Reacting a compound of formula VII with sodium acetate to produce a compound of formula VI
c) Hydrolysis of the product of step (b) to hydroxy methyl oxazolidinone compound of formula V
2. The process according to claim 1 wherein the quantity of R-epichlorohydrin is
at least 1.25 molar equivalent per equivalent of formula IX.
3. The process according to claim 1 wherein the reaction in step (a) is carried out
with use of solvent and at about 70-80 °C.
4. The process according to claim 3, wherein the solvent is tertiary butanol.
5. The process according to claim 1 chloromethyl oxazolidinone is crystallized from
Single or mixed solvent system .
6. The process according to claim 5, wherein the solvent is selected from ethylacetate,
n-butyl acetate and methyltertiarybutylether.
7. The process according to claim 6, wherein the solvent is n-butyl acetate and
methyltertiarybutylether.
8. The process according to claim 1(b), wherein the sodium acetate is anhydrous.
9. The process according to claim 8, wherein the quantity of sodium acetate is
at least 2.0 molar equivalents to compound of formula VII.
10. The process according to claim 8, wherein the reaction is carried out at a
temperature of 120 °C.
11. The process according to claim 8, wherein the reaction solvent is selected
from aprotic solvent.
12. The process according to claim 11, wherein the reaction solvent is DMF.
13. The process according to claim 1, wherein reaction of the said acetyl oxazolidinone with a base is in presence of solvent or mixture of solvents.
14. The process according to claim 13, where in the base is sodium tert. butoxide.
15. The process according to claim 13, wherein the reaction is carried out in solvent mixture of THF and water and finaly the product is being isolated from the methylen di chloride and isopropylehter
16. The process according to claim 13, wherein the quantity of sodium
tert. butoxide is at least one molar equivalent to compound of formula VI.
17. The process according to claim 13, wherein the reaction temperature is about
10-15 °C.
| # | Name | Date |
|---|---|---|
| 1 | Form-1.pdf | 2011-09-04 |
| 2 | 2451-CHE-2010 REQUEST FOR POST DATING 21-02-2012.pdf | 2012-02-21 |
| 3 | 2451-CHE-2010 POWER OF ATTORNEY 21-02-2012.pdf | 2012-02-21 |
| 4 | 2451-CHE-2010 FORM-13 21-02-2012.pdf | 2012-02-21 |
| 5 | 2451-CHE-2010 FORM-18 02-03-2012.pdf | 2012-03-02 |
| 6 | 2451-CHE-2010 CORRESPONDENCE OTHERS 02-03-2012.pdf | 2012-03-02 |
| 7 | 2451-CHE-2010 FORM-13 03-04-2014.pdf | 2014-04-03 |
| 8 | FORM-13 [address change of the service].pdf | 2014-04-04 |
| 9 | 2451-CHE-2010 CORRESPONDENCE OTHERS 12-02-2015.pdf | 2015-02-12 |
| 10 | 2451-CHE-2010-FER.pdf | 2017-01-23 |
| 11 | 2451-CHE-2010-FORM 3 [13-07-2017(online)].pdf | 2017-07-13 |
| 12 | 2451-CHE-2010-RELEVANT DOCUMENTS [14-07-2017(online)].pdf | 2017-07-14 |
| 13 | 2451-CHE-2010-FORM 3 [06-11-2021(online)].pdf | 2021-11-06 |
| 13 | 2451-CHE-2010-Proof of Right (MANDATORY) [14-07-2017(online)].pdf | 2017-07-14 |
| 14 | 2451-CHE-2010-PETITION UNDER RULE 137 [14-07-2017(online)].pdf | 2017-07-14 |
| 14 | 2451-CHE-2010-US(14)-ExtendedHearingNotice-(HearingDate-17-08-2021).pdf | 2021-10-03 |
| 15 | Correspondence by Agent_Form 1_18-07-2017.pdf | 2017-07-18 |
| 16 | 2451-CHE-2010-OTHERS [20-07-2017(online)].pdf | 2017-07-20 |
| 16 | 2451-CHE-2010-US(14)-ExtendedHearingNotice-(HearingDate-30-11-2021).pdf | 2021-10-03 |
| 17 | 2451-CHE-2010-FER_SER_REPLY [20-07-2017(online)].pdf | 2017-07-20 |
| 18 | 2451-CHE-2010-CORRESPONDENCE [20-07-2017(online)].pdf | 2017-07-20 |
| 18 | 2451-CHE-2010-REQUEST FOR ADJOURNMENT OF HEARING UNDER RULE 129A [23-09-2021(online)].pdf | 2021-09-23 |
| 19 | 2451-CHE-2010-COMPLETE SPECIFICATION [20-07-2017(online)].pdf | 2017-07-20 |
| 19 | 2451-CHE-2010-Correspondence to notify the Controller [21-08-2021(online)].pdf | 2021-08-21 |
| 20 | 2451-CHE-2010 Hearing Adjournment Notice 13-08-2021.pdf | 2021-08-13 |
| 20 | 2451-CHE-2010-CLAIMS [20-07-2017(online)].pdf | 2017-07-20 |
| 21 | 2451-CHE-2010-ABSTRACT [20-07-2017(online)].pdf | 2017-07-20 |
| 21 | 2451-CHE-2010-Correspondence_Hearing Adjournment Notice_13-08-2021.pdf | 2021-08-13 |
| 22 | 2451-CHE-2010 Pre-grant Opposition Notice 09-08-2021.pdf | 2021-08-09 |
| 22 | 2451-CHE-2010-Representation,including the statement and evidence [27-07-2017(online)].pdf_1.pdf | 2017-07-27 |
| 23 | 2451-CHE-2010-Pre-Grant Opposition Notice_09-08-2021.pdf | 2021-08-09 |
| 23 | 2451-CHE-2010-Representation,including the statement and evidence [27-07-2017(online)].pdf | 2017-07-27 |
| 24 | 2451-CHE-2010-Correspondence to notify the Controller [21-07-2021(online)].pdf | 2021-07-21 |
| 24 | 2451-CHE-2010-PRE GRANT OPPOSITION FORM [27-07-2017(online)].pdf | 2017-07-27 |
| 25 | 2451-CHE-2010-PRE GRANT OPPOSITION DOCUMENT [27-07-2017(online)].pdf | 2017-07-27 |
| 25 | 2451-CHE-2010-Representation,including the statement and evidence [20-07-2021(online)].pdf | 2021-07-20 |
| 26 | 2451-CHE-2010-Correspondence to notify the Controller [03-06-2021(online)].pdf | 2021-06-03 |
| 26 | 2451-CHE-2010-OTHERS [27-07-2017(online)].pdf | 2017-07-27 |
| 27 | 2451-CHE-2010-RELEVANT DOCUMENTS [01-06-2020(online)].pdf | 2020-06-01 |
| 27 | 2451-CHE-2010-Representation,including the statement and evidence [28-07-2017(online)].pdf | 2017-07-28 |
| 28 | 2451-CHE-2010-Form-26, Affidavit_19-05-2020.pdf | 2020-05-19 |
| 28 | Correspondence by Agent_Form 7A PRE GRANT OPPOSITION_31-07-2017.pdf | 2017-07-31 |
| 29 | 2451-CHE-2010-FORM 3 [24-11-2017(online)].pdf | 2017-11-24 |
| 29 | 2451-CHE-2010-OTHERS [28-03-2020(online)].pdf | 2020-03-28 |
| 30 | 2451-CHE-2010-FORM 3 [16-04-2018(online)].pdf | 2018-04-16 |
| 30 | 2451-CHE-2010-PRE GRANT OPPOSITION DOCUMENT [28-03-2020(online)].pdf | 2020-03-28 |
| 31 | 2451-CHE-2010-Statement and Evidence (MANDATORY) [18-04-2018(online)].pdf | 2018-04-18 |
| 32 | 2451-CHE-2010-Response to office action (Mandatory) [26-04-2018(online)].pdf | 2018-04-26 |
| 33 | 2451-CHE-2010-Response to office action (Mandatory) [07-05-2018(online)].pdf | 2018-05-07 |
| 33 | 2451-CHE-2010-Written submissions and relevant documents [20-03-2020(online)]-1.pdf | 2020-03-20 |
| 34 | 2451-CHE-2010-RELEVANT DOCUMENTS [17-05-2018(online)].pdf | 2018-05-17 |
| 34 | 2451-CHE-2010-Written submissions and relevant documents [20-03-2020(online)].pdf | 2020-03-20 |
| 35 | 2451-CHE-2010 Pre-grant Hearing Notice 03-12-2019.pdf | 2019-12-03 |
| 36 | 2451-CHE-2010-HearingNoticeLetter-(DateOfHearing-27-12-2019).pdf | 2019-12-04 |
| 37 | 2451-CHE-2010-Written submissions and relevant documents [17-03-2020(online)].pdf | 2020-03-17 |
| 37 | 2451-CHE-2010-Correspondence to notify the Controller (Mandatory) [18-12-2019(online)].pdf | 2019-12-18 |
| 38 | 2451-CHE-2010-REQUEST FOR ADJOURNMENT OF HEARING UNDER RULE 129A [20-12-2019(online)].pdf | 2019-12-20 |
| 39 | Correspondence by Office_Pre-Grant Opposition Notice_23-12-2019.pdf | 2019-12-23 |
| 40 | 2451-CHE-2010-ExtendedHearingNoticeLetter-(DateOfHearing-30-01-2020).pdf | 2019-12-26 |
| 41 | 2451-CHE-2010-Correspondence to notify the Controller (Mandatory) [31-12-2019(online)].pdf | 2019-12-31 |
| 42 | 2451-CHE-2010-REQUEST FOR ADJOURNMENT OF HEARING UNDER RULE 129A [25-01-2020(online)].pdf | 2020-01-25 |
| 43 | 2451-CHE-2010-Hearing Adjournment Request_06-02-2020.pdf | 2020-02-06 |
| 44 | 2451-CHE-2010-Correspondence to notify the Controller [11-02-2020(online)].pdf | 2020-02-11 |
| 45 | 2451-CHE-2010-PETITION UNDER RULE 138 [25-02-2020(online)].pdf | 2020-02-25 |
| 46 | 2451-CHE-2010-RELEVANT DOCUMENTS [26-02-2020(online)].pdf | 2020-02-26 |
| 47 | 2451-CHE-2010-ExtendedHearingNoticeLetter-(DateOfHearing-03-03-2020).pdf | 2020-02-28 |
| 48 | 2451-CHE-2010-RELEVANT DOCUMENTS [02-03-2020(online)].pdf | 2020-03-02 |
| 49 | 2451-CHE-2010-PETITION UNDER RULE 138 [03-03-2020(online)].pdf | 2020-03-03 |
| 50 | 2451-CHE-2010-PETITION UNDER RULE 137 [03-03-2020(online)].pdf | 2020-03-03 |
| 51 | 2451-CHE-2010-RELEVANT DOCUMENTS [16-03-2020(online)].pdf | 2020-03-16 |
| 52 | 2451-CHE-2010-Written submissions and relevant documents [17-03-2020(online)].pdf | 2020-03-17 |
| 53 | 2451-CHE-2010-PETITION UNDER RULE 138 [17-03-2020(online)].pdf | 2020-03-17 |
| 54 | 2451-CHE-2010-PETITION UNDER RULE 138 [17-03-2020(online)]-1.pdf | 2020-03-17 |
| 55 | 2451-CHE-2010-Written submissions and relevant documents [20-03-2020(online)].pdf | 2020-03-20 |
| 56 | 2451-CHE-2010-Written submissions and relevant documents [20-03-2020(online)]-1.pdf | 2020-03-20 |
| 57 | 2451-CHE-2010-Representation,including the statement and evidence [20-03-2020(online)].pdf | 2020-03-20 |
| 58 | 2451-CHE-2010-PRE GRANT OPPOSITION FORM [28-03-2020(online)].pdf | 2020-03-28 |
| 59 | 2451-CHE-2010-PRE GRANT OPPOSITION DOCUMENT [28-03-2020(online)].pdf | 2020-03-28 |
| 60 | 2451-CHE-2010-OTHERS [28-03-2020(online)].pdf | 2020-03-28 |
| 61 | 2451-CHE-2010-Form-26, Affidavit_19-05-2020.pdf | 2020-05-19 |
| 62 | 2451-CHE-2010-RELEVANT DOCUMENTS [01-06-2020(online)].pdf | 2020-06-01 |
| 63 | 2451-CHE-2010-Correspondence to notify the Controller [03-06-2021(online)].pdf | 2021-06-03 |
| 64 | 2451-CHE-2010-Representation,including the statement and evidence [20-07-2021(online)].pdf | 2021-07-20 |
| 65 | 2451-CHE-2010-Correspondence to notify the Controller [21-07-2021(online)].pdf | 2021-07-21 |
| 66 | 2451-CHE-2010-Pre-Grant Opposition Notice_09-08-2021.pdf | 2021-08-09 |
| 67 | 2451-CHE-2010 Pre-grant Opposition Notice 09-08-2021.pdf | 2021-08-09 |
| 68 | 2451-CHE-2010-Correspondence_Hearing Adjournment Notice_13-08-2021.pdf | 2021-08-13 |
| 69 | 2451-CHE-2010 Hearing Adjournment Notice 13-08-2021.pdf | 2021-08-13 |
| 70 | 2451-CHE-2010-Correspondence to notify the Controller [21-08-2021(online)].pdf | 2021-08-21 |
| 71 | 2451-CHE-2010-REQUEST FOR ADJOURNMENT OF HEARING UNDER RULE 129A [23-09-2021(online)].pdf | 2021-09-23 |
| 72 | 2451-CHE-2010-Correspondence to notify the Controller [29-09-2021(online)].pdf | 2021-09-29 |
| 73 | 2451-CHE-2010-US(14)-ExtendedHearingNotice-(HearingDate-30-11-2021).pdf | 2021-10-03 |
| 74 | 2451-CHE-2010-US(14)-ExtendedHearingNotice-(HearingDate-29-09-2021).pdf | 2021-10-03 |
| 75 | 2451-CHE-2010-US(14)-ExtendedHearingNotice-(HearingDate-17-08-2021).pdf | 2021-10-03 |
| 76 | 2451-CHE-2010-FORM 3 [06-11-2021(online)].pdf | 2021-11-06 |
| 77 | 2451-CHE-2010-Statement and Evidence [08-11-2021(online)].pdf | 2021-11-08 |
| 78 | 2451-CHE-2010-REQUEST FOR ADJOURNMENT OF HEARING UNDER RULE 129A [25-11-2021(online)].pdf | 2021-11-25 |
| 79 | 2451-CHE-2010-US(14)-ExtendedHearingNotice-(HearingDate-10-03-2022).pdf | 2022-01-26 |
| 80 | 2451-CHE-2010-Correspondence to notify the Controller [28-01-2022(online)].pdf | 2022-01-28 |
| 81 | 2451-CHE-2010-Correspondence to notify the Controller [02-03-2022(online)].pdf | 2022-03-02 |
| 82 | 2451-CHE-2010-REQUEST FOR ADJOURNMENT OF HEARING UNDER RULE 129A [06-03-2022(online)].pdf | 2022-03-06 |
| 83 | 2451-CHE-2010-POA [17-02-2023(online)].pdf | 2023-02-17 |
| 84 | 2451-CHE-2010-FORM 13 [17-02-2023(online)].pdf | 2023-02-17 |
| 85 | 2451-CHE-2010-RELEVANT DOCUMENTS [22-02-2023(online)].pdf | 2023-02-22 |
| 86 | 2451-CHE-2010-RELEVANT DOCUMENTS [29-03-2023(online)].pdf | 2023-03-29 |
| 87 | 2451-CHE-2010-PatentCertificate26-07-2024.pdf | 2024-07-26 |
| 88 | 2451-CHE-2010-IntimationOfGrant26-07-2024.pdf | 2024-07-26 |
| 1 | 2451CHE2010SEARCH_20-01-2017.pdf |